{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T22:16:19Z","timestamp":1794435379167,"version":"4.9.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,10,16]],"date-time":"2020-10-16T00:00:00Z","timestamp":1602806400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,10,16]],"date-time":"2020-10-16T00:00:00Z","timestamp":1602806400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s40744-020-00246-z","type":"journal-article","created":{"date-parts":[[2020,10,16]],"date-time":"2020-10-16T20:03:07Z","timestamp":1602878587000},"page":"1045-1052","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Immune Checkpoint Inhibitor-Associated Scleroderma-Like Syndrome: A Report of a Pembrolizumab-Induced \u201cEosinophilic Fasciitis-Like\u201d Case and a Review of the Literature"],"prefix":"10.1007","volume":"7","author":[{"given":"Christina","family":"Salamaliki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena E.","family":"Solomou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2511-8083","authenticated-orcid":false,"given":"Stamatis-Nick C.","family":"Liossis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,16]]},"reference":[{"issue":"4","key":"246_CR1","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252\u201364. https:\/\/doi.org\/10.1038\/nrc3239.","journal-title":"Nat Rev Cancer"},{"issue":"11","key":"246_CR2","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1002\/acr.23177","volume":"69","author":"LC Cappelli","year":"2017","unstructured":"Cappelli LC, Gutierrez AK, Bingham CO, Shah AA. Rheumatic and musculoskeletal immune-related adverse events due to immune checkpoint inhibitors: a systematic review of the literature. Arthritis Care Res. 2017;69(11):1751\u201363. https:\/\/doi.org\/10.1002\/acr.23177.","journal-title":"Arthritis Care Res"},{"key":"246_CR3","doi-asserted-by":"publisher","first-page":"vii40","DOI":"10.1093\/rheumatology\/kez297","volume":"58","author":"N Abdel-Wahab","year":"2019","unstructured":"Abdel-Wahab N, Suarez-Almazor ME. Frequency and distribution of various rheumatic disorders associated with checkpoint inhibitor therapy. Rheumatol (United Kingdom). 2019;58:vii40\u20138. https:\/\/doi.org\/10.1093\/rheumatology\/kez297.","journal-title":"Rheumatol (United Kingdom)"},{"issue":"9","key":"246_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms21093389","volume":"21","author":"K Melissaropoulos","year":"2020","unstructured":"Melissaropoulos K, Klavdianou K, Filippopoulou A, Kalofonou F, Kalofonos H, Daoussis D. Rheumatic manifestations in patients treated with immune checkpoint inhibitors. Int J Mol Sci. 2020;21(9):1\u201318. https:\/\/doi.org\/10.3390\/ijms21093389.","journal-title":"Int J Mol Sci"},{"key":"246_CR5","doi-asserted-by":"publisher","first-page":"102595","DOI":"10.1016\/j.autrev.2020.102595","volume":"19","author":"J Roberts","year":"2020","unstructured":"Roberts J, Ennis D, Hudson M, et al. Rheumatic immune-related adverse events associated with cancer immunotherapy: a nationwide multi-center cohort. Autoimmun Rev. 2020;19:102595. https:\/\/doi.org\/10.1016\/j.autrev.2020.102595.","journal-title":"Autoimmun Rev."},{"key":"246_CR6","first-page":"21224","volume":"43","author":"LC Cappelli","year":"2017","unstructured":"Cappelli LC, Shah AA, Iii COB. Immune-related adverse effects of cancer immunotherapy\u2014implications for rheumatology. Rheumatic Disease Clin N Am. 2017;43:21224.","journal-title":"Rheumatic Disease Clin N Am"},{"key":"246_CR7","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.ejca.2018.09.027","volume":"105","author":"EL Mitchell","year":"2018","unstructured":"Mitchell EL, Lau PKH, Khoo C, et al. Rheumatic immune-related adverse events secondary to anti-programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: a case series. Eur J Cancer. 2018;105:88\u2013102. https:\/\/doi.org\/10.1016\/j.ejca.2018.09.027.","journal-title":"Eur J Cancer"},{"key":"246_CR8","doi-asserted-by":"publisher","first-page":"vii 68","DOI":"10.1093\/rheumatology\/kez295","volume":"58","author":"M Kostine","year":"2019","unstructured":"Kostine M, Truchetet ME, Schaeverbeke T. Clinical characteristics of rheumatic syndromes associated with checkpoint inhibitors therapy. Rheumatol (United Kingdom). 2019;58:vii 68-vii 74. https:\/\/doi.org\/10.1093\/rheumatology\/kez295.","journal-title":"Rheumatol (United Kingdom)."},{"issue":"4\u20135","key":"246_CR9","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.autrev.2014.01.019","volume":"13","author":"I Pinal-Fernandez","year":"2014","unstructured":"Pinal-Fernandez I, Selva-O\u2019Callaghan A, Grau JM. Diagnosis and classification of eosinophilic fasciitis. Autoimmun Rev. 2014;13(4\u20135):379\u201382. https:\/\/doi.org\/10.1016\/j.autrev.2014.01.019.","journal-title":"Autoimmun Rev"},{"issue":"1","key":"246_CR10","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.rdc.2007.11.001","volume":"34","author":"F Boin","year":"2009","unstructured":"Boin F, Hummers LK. Scleroderma-like fibrosing disorders. Rheum Clin Disord. 2009;34(1):199\u2013220. https:\/\/doi.org\/10.1016\/j.rdc.2007.11.001.","journal-title":"Rheum Clin Disord"},{"issue":"8","key":"246_CR11","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1111\/1346-8138.14160","volume":"45","author":"M Jinnin","year":"2018","unstructured":"Jinnin M, Yamamoto T, Asano Y, et al. Diagnostic criteria, severity classification and guidelines of eosinophilic fasciitis. J Dermatol. 2018;45(8):881\u201390. https:\/\/doi.org\/10.1111\/1346-8138.14160.","journal-title":"J Dermatol"},{"issue":"1","key":"246_CR12","doi-asserted-by":"publisher","first-page":"117","DOI":"10.3329\/jhpn.v30i1.11292","volume":"30","author":"MN Islam","year":"2012","unstructured":"Islam MN, Islam MA, Abdal SJ, Azad MAK, Ahmedullah AK, Haq SA. Eosinophilic fasciitis: What matters in management in a developing country\u2014a case report with two and a half-year follow-up. J Heal Popul Nutr. 2012;30(1):117\u201320. https:\/\/doi.org\/10.3329\/jhpn.v30i1.11292.","journal-title":"J Heal Popul Nutr"},{"issue":"4","key":"246_CR13","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/0049-0172(88)90008-X","volume":"17","author":"S Lakhanpal","year":"1988","unstructured":"Lakhanpal S, Ginsburg WW, Michet CJ, Doyle JA, Moore SB. Eosinophilic fasciitis: clinical spectrum and therapeutic response in 52 cases. Semin Arthritis Rheum. 1988;17(4):221\u201331. https:\/\/doi.org\/10.1016\/0049-0172(88)90008-X.","journal-title":"Semin Arthritis Rheum"},{"key":"246_CR14","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/bcr-2017-223249","volume":"2018","author":"MJS Parker","year":"2018","unstructured":"Parker MJS, Roberts ME, Lorigan PC, Du Plessis DG, Chinoy H. Autoimmune fasciitis triggered by the anti-programmed cell death-1 monoclonal antibody nivolumab. BMJ Case Rep. 2018;2018:3\u20136. https:\/\/doi.org\/10.1136\/bcr-2017-223249.","journal-title":"BMJ Case Rep"},{"issue":"2","key":"246_CR15","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1634\/theoncologist.2019-0508","volume":"25","author":"KK Chan","year":"2020","unstructured":"Chan KK, Magro C, Shoushtari A, et al. Eosinophilic fasciitis following checkpoint inhibitor therapy: four cases and a review of literature. Oncologist. 2020;25(2):140\u20139. https:\/\/doi.org\/10.1634\/theoncologist.2019-0508.","journal-title":"Oncologist"},{"issue":"3","key":"246_CR16","doi-asserted-by":"publisher","first-page":"101","DOI":"10.4103\/jipo.jipo_8_19","volume":"2","author":"Y Wissam","year":"2019","unstructured":"Wissam Y, Belcaid L, Wittoek R, et al. Eosinophilic fasciitis in a patient treated by atezolizumab for metastatic triple-negative breast cancer. J Immunother Precis Oncol. 2019;2(3):101. https:\/\/doi.org\/10.4103\/jipo.jipo_8_19.","journal-title":"J Immunother Precis Oncol"},{"issue":"3","key":"246_CR17","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1158\/2326-6066.CIR-15-0186","volume":"4","author":"L Khoja","year":"2016","unstructured":"Khoja L, Maurice C, Chappell M, et al. Eosinophilic fasciitis and acute encephalopathy toxicity from pembrolizumab treatment of a patient with metastatic melanoma. Cancer Immunol Res. 2016;4(3):175\u20138. https:\/\/doi.org\/10.1158\/2326-6066.CIR-15-0186.","journal-title":"Cancer Immunol Res"},{"issue":"3","key":"246_CR18","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.autrev.2018.01.003","volume":"17","author":"M Lidar","year":"2018","unstructured":"Lidar M, Giat E, Garelick D, et al. Rheumatic manifestations among cancer patients treated with immune checkpoint inhibitors. Autoimmun Rev. 2018;17(3):284\u20139. https:\/\/doi.org\/10.1016\/j.autrev.2018.01.003.","journal-title":"Autoimmun Rev"},{"issue":"12","key":"246_CR19","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1111\/imj.14126","volume":"48","author":"A Rischin","year":"2018","unstructured":"Rischin A, Brady B, McLean C, Ostor AJK. Immune checkpoint inhibitor-induced lymphocytic fasciitis. Intern Med J. 2018;48(12):1550\u20132. https:\/\/doi.org\/10.1111\/imj.14126.","journal-title":"Intern Med J"},{"issue":"1","key":"246_CR20","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.1016\/j.jtho.2018.09.016","volume":"14","author":"E Le Tallec","year":"2019","unstructured":"Le Tallec E, Ricordel C, Triquet L, et al. An original case of an association of eosinophilic fasciitis with cholangitis induced by nivolumab. J Thorac Oncol. 2019;14(1):e13\u20135. https:\/\/doi.org\/10.1016\/j.jtho.2018.09.016.","journal-title":"J Thorac Oncol"},{"issue":"1","key":"246_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/rap\/rkaa001","volume":"4","author":"N Ollier","year":"2020","unstructured":"Ollier N, Tournier E, Meyer N, et al. Nivolumab-induced eosinophilic fasciitis: a case report. Rheumatol Adv Pract. 2020;4(1):1\u20133. https:\/\/doi.org\/10.1093\/rap\/rkaa001.","journal-title":"Rheumatol Adv Pract"},{"issue":"4","key":"246_CR22","doi-asserted-by":"publisher","first-page":"e302","DOI":"10.1111\/ajd.12836","volume":"59","author":"JJ Andr\u00e9s-Lencina","year":"2018","unstructured":"Andr\u00e9s-Lencina JJ, Burillo-Mart\u00ednez S, Arag\u00f3n-Miguel R, et al. Eosinophilic fasciitis and lichen sclerosus in a patient treated with nivolumab. Australas J Dermatol. 2018;59(4):e302\u20134. https:\/\/doi.org\/10.1111\/ajd.12836.","journal-title":"Australas J Dermatol"},{"issue":"10","key":"246_CR23","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1093\/rheumatology\/kez164","volume":"58","author":"F Toussaint","year":"2019","unstructured":"Toussaint F, Hammon M, Erdmann M, et al. Checkpoint inhibitor-induced eosinophilic fasciitis following high eosinophilia associated with complete response. Rheumatol (United Kingdom). 2019;58(10):1875\u20137. https:\/\/doi.org\/10.1093\/rheumatology\/kez164.","journal-title":"Rheumatol (United Kingdom)"},{"issue":"12","key":"246_CR24","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1093\/rheumatology\/kex369","volume":"56","author":"D Daoussis","year":"2017","unstructured":"Daoussis D, Kraniotis P, Liossis SN, Solomou A. Immune checkpoint inhibitor-induced myo-fasciitis. Rheumatol (United Kingdom). 2017;56(12):2161. https:\/\/doi.org\/10.1093\/rheumatology\/kex369.","journal-title":"Rheumatol (United Kingdom)"},{"issue":"3","key":"246_CR25","doi-asserted-by":"publisher","first-page":"225","DOI":"10.2174\/1574886314666190528121039","volume":"14","author":"S Kobak","year":"2019","unstructured":"Kobak S. Pembrolizumab-induced seronegative arthritis and fasciitis in a patient with lung adenocarcinoma. Curr Drug Saf. 2019;14(3):225\u20139. https:\/\/doi.org\/10.2174\/1574886314666190528121039.","journal-title":"Curr Drug Saf"},{"issue":"10","key":"246_CR26","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1016\/j.autrev.2018.05.002","volume":"17","author":"J Narv\u00e1ez","year":"2018","unstructured":"Narv\u00e1ez J, Juarez-L\u00f3pez P, LLuch J, et al. Rheumatic immune-related adverse events in patients on anti-PD-1 inhibitors: fasciitis with myositis syndrome as a new complication of immunotherapy. Autoimmun Rev. 2018;17(10):1040\u20135. https:\/\/doi.org\/10.1016\/j.autrev.2018.05.002.","journal-title":"Autoimmun Rev"},{"issue":"5","key":"246_CR27","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1093\/rheumatology\/kez361","volume":"59","author":"D Daoussis","year":"2020","unstructured":"Daoussis D, Kraniotis P, Filippopoulou A, et al. An MRI study of immune checkpoint inhibitor-induced musculoskeletal manifestations myofasciitis is the prominent imaging finding. Rheumatol (United Kingdom). 2020;59(5):1041\u201350. https:\/\/doi.org\/10.1093\/rheumatology\/kez361.","journal-title":"Rheumatol (United Kingdom)."}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-020-00246-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-020-00246-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-020-00246-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,16]],"date-time":"2021-10-16T06:56:12Z","timestamp":1634367372000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40744-020-00246-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,16]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["246"],"URL":"https:\/\/doi.org\/10.1007\/s40744-020-00246-z","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"value":"2198-6576","type":"print"},{"value":"2198-6584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,16]]},"assertion":[{"value":"14 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}